LIST OF NTDs
1. Buruli
ulcer 2.
Hydatidosis
2. Cholera 4.
Leishmaniasis
5.
Cysticercosis 6.
Lymphatic filariasis
7.
Dracunculiasis 8.
Onchocerciasis
9.
Foodborne trematode infections 10. Schistosomiasis
11.
Dengue haemorrhagic fever 12. STHs
13.
African Trypanosomiasis
l
Affect approx. 1 billion people or 1/6 of world
popn (1 in 6)
l
Affect poorest and most vulnerable popns
l
Mainly tropical & sub-tropical areas
l
Life-long infections (morbidity, physical disability, gross disfigurement)
l
Acute infections (transient, severe, fatal)
l
Social stigmatization and abuse
l
Available effective, inexpensive or donated
drugs for their prevention & control (e.g. leprosy, trachoma, LF,
onchocerciasis, schistosomiasis, STHs;
l
Simple diagnostic tools & safe, effective
treatment give prospects (Buruli ulcer, cholera, Afr. Trypanosomiasis,
leishmaniasis)
l
Vector control tools
WHO strategies
•
Preventive Chemotherapy & Transmission
Control
•
Innovative & Intensified Disease Management
•
Disease Control in Humanitarian Emergencies
•
Vector Control Management
Global Buruli Ulcer
Initiative (GBUI)
•
Raising awareness
•
Improving access to early diagnosis, treatment
& prevention of disability
•
Strengthening surveillance systems
•
Priority research
Cholera
Treatment: ORS or IVF (severe)
Prevention & control:
1.
Case management – rehydration
2.
Surveillance systems (IHR)
3.
Multisectoral approach
4.
Water supply & sanitation
5.
Personal hygiene, food safety, HE
6.
Oral cholera vaccines
Dracunculiasis - Eradication
Programme
•
Effective case containment measures
•
Community-based surveillance
•
Target specific interventions
•
Epidemiological mapping
•
Sustain advocacy
•
Certification of disease eradication
Lymphatic filariasis
(elephantiasis) GPELF strategies:
1.
MDA (DEC+albendazole; ivermectin + albendazole)
2.
Mapping
3.
Care & prevention of LF-related disability
Onchocerciasis (River
blindness)
•
CDTI
•
Vector control (in some African countries)
Schistosomiasis & STHs
Reasons for new control
strategy:
1.
Reduced drug costs
2.
Goal of the programme: Reduce intensity
Strategy: Piggy-backed into
existing networks:
1.
School system
2.
Involving non-medical people
3.
Special health campaigns
4.
Stocking local health posts & pharmacies
with drugs
Benefits:
1.
Reduce cost delivery & treatment
2.
Stable programme
3.
Long lasting
4.
Improve health status (children & pregnant
women
)
Leprosy
Final Push to Eliminate Leprosy:
1.
Diagnosis & treatment (free)
2.
Capacity building of health workers
3.
Increased awareness of early signs &
motivating people to seek treatment
4.
Ensuring treatment of all affected
MDT regimens
PB adult treatment (PB adult blister pack - Green): 6 packs
Once a month: Day 1
-
2 capsules of rifampicin (300mgx2)
-
1 tablet of dapsone (100mg)
Once a day: Days 2-28
- 1 tablet of dapsone (100mg)
PB child treatment 10-14 yrs (PB child blister pack - Blue): 6 packs
Once a month: Day 1
-
2 capsules of rifampicin (300mg+150mg)
-
1 tablet of dapsone (50mg)
Once a day: Days 2-28
- 1 tablet of dapsone (50mg)
MB adult treatment (MB adult blister pack - Purple): 12 packs
Once a month: Day 1
-
2 capsules of rifampicin (300mgx2)
-
3 capsules of clofazimine (100mgx3)
-
1 tablet of dapsone (100mg)
Once a day: Days 2-28
- 1 capsule of clofazimine (50mg)
- 1 tablet of dapsone (100mg)
MB child treatment 10-14 yrs (MB child blister pack - Brown): 12 packs
Once a month: Day 1
-
2 capsules of rifampicin (300mg+150mg)
-
3 capsules of clofazimine (50mgx3)
-
1 tablet of dapsone (50mg)
Once a day: Days 2-28
- 1 capsule of clofazimine every other day (50mg)
- 1 tablet of dapsone (50mg)